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Abstract
mRNA-display is an amplification-based, iterative rounds of in vitro protein selection technique
that circumvents a number of difficulties associated with yeast two-hybrid and phage display.
Because of the covalent linkage between the genotype and the phenotype, mRNA-display provides
a powerful means for reading and amplifying a peptide or protein sequence after it has been
selected from a library with very high diversity. The purpose of this article is to provide a
summary of the field and practical framework of mRNA-display-based selections. We summarize
the advantages and limitations of selections using mRNA-display as well as the recent
applications, namely, the identification of novel affinity reagents, target-binding partners, and
enzyme substrates from synthetic peptide or natural proteome libraries. Practically, we provide a
detailed procedure for performing mRNA-display-based selections with the aim of identifying
protease substrates and binding partners of a target protein. Furthermore, we describe how to
confirm the function of the selected protein sequences by biochemical assays and bioinformatic
tools.
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1. Introduction
1.1. Principle of mRNA-display selection
mRNA-display permits the efficient identification of peptide sequences, via in vitro
selection, with desired characteristics from a natural protein or a combinatorial peptide
library [1–3]. The key feature of the technique is the peptide covalent linkage to its own
mRNA (at 3’ end). This is accomplished by synthesis and in vitro translation of an mRNA
template with puromycin attached to its 3’ end via a short DNA linker. During in vitro
translation, when the ribosome reaches the RNA-DNA junction and translation pauses,
puromycin, an antibiotic that mimics the aminoacyl moiety of tRNA, enters the ribosome
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“A” site and accepts the nascent polypeptide by forming a peptide bond. This results in
tethering the nascent peptide to its own mRNA (Fig. 1). Since the mRNA (genotype) and
peptide (phenotype) sequences are covalently linked in a single molecule, mRNA-display
permits effective amplification of a peptide or protein sequence following selection based on
its function. Iterative rounds of selection and amplification enable enrichment of rare
sequences with desired characteristics. In theory, any peptide or protein sequence with
desired characteristics may be selected by mRNA-display. Thus far, the applications of
mRNA-display notably include, but are not limited to, mapping of the protein-protein and
nucleic acid-protein interaction networks, identification of drug-binding targets, elucidation
of the enzyme-substrate interactions, the development of novel and improvement of existing
affinity reagents [4–11]. Fig. 1 shows the general procedure for the selection of the
downstream substrates of a protease of interest (option A) and for the identification of the
binding partners of a target of interest (option B).
Here, we briefly summarize the major developments, advantages, limitations and
applications of mRNA-display, provide a practical step-by-step procedure of the selection
process from mRNA-displayed protein libraries, focusing on the selection for binding
partners and protease substrates, and conclude by pointing out the future direction of the
field.
1.2. Advantage of mRNA-display selection
Compared to related protein selection methods, mRNA-display has notable advantages.
First, the covalent linkage of the genotype to the phenotype allows rapid identification of
isolated proteins with wide variety of desired characteristics following a functional
selection. Second, the library complexity, with as many as 1012–1014 unique sequences,
close to that of the RNA or DNA pools, can be readily generated and selected, several orders
of magnitude higher than phage display can reach. In this case, the main advantages are that
the likelihood of selecting rare sequences and that the diversity of the selected sequences
isolated is significantly increased. Third, the covalent linkage between the protein and its
mRNA permits the utilization of any arbitrary condition in a functional selection with
tunable stringency without compromising the recovery of the selected sequences. The
success of a selection is highly dependent on the development of a selection scheme that
allows for specific enrichment of sequences with desired characteristics, while minimizing
nonspecific sequences. Many of the current technologies, including ribosome-display, are
limited in terms of the binding conditions that may be used in a given screen. For example,
ribosome-display with the fragile noncovalent conjugation between genotype and phenotype
requires mild selection conditions. In contrast, the phenotype–genotype linkage in mRNA-
display is covalent and highly stable, making it possible to perform many types of selections
under very stringent conditions. mRNA-display is an entirely in vitro selection technique
that exploits cell-free translation systems for the efficient generation of peptide sequences.
Since the expression and selection steps are both performed in vitro and transformation is
not necessary, the library complexity size is determined by the genetic material, which can
be scaled up in the laboratory to increase library diversity. The amount of DNA
oligonucleotides that can be synthesized, the volume of PCR that can be performed to
generate the cDNA library and the volume of in vitro translation reaction to express the
protein library can also be scaled up and tailored to increase the diversity [12]. As such,
peptide or protein libraries with 1012–1014 unique sequences can be obtained. In contrast, in
vivo protein selection methods are limited to small, low complexity libraries due to
inefficient transformations or transfections of the starting cDNA library into the organism of
choice. The phage display is typically around 109, whereas the library size for cell-based
selections, such as the yeast two-hybrid system, bacteria and yeast surface display, is
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approximately 106 [13,14]. In the IVC (in vitro compartmentalization) system using water-
in-oil micro-droplets, the diversity of the library is typically limited to less than 109 [15].
For totally or partially randomized peptide or protein libraries, the much higher diversity
provides the opportunity for exploration of the sequence space to a greater depth for the
search of target-binding partners. Practically, this larger library complexity raises the
probability of finding target-binding sequences with improved affinity and specificity.
According to Lancet and coworkers’ model of olfactory receptors and antibodies, the
affinity of the best binding partners increased approximately 300-fold when the library size
increased 10,000-times [12,16]. Compared with totally synthetic protein libraries, natural
proteome libraries have much lower diversities. In theory, all of the full-length proteins in
the proteome can be displayed [17,18]. However, this task requires the amplification of all
genes of interest using gene-specific primers, which significantly reduces the throughput and
increases the costs of the selection. To circumvent this issue, one approach is to construct a
cDNA library from isolated mRNAs using random reverse-transcription primers to cover all
the open reading frame regions in the genome. Therefore, a much larger cDNA library, a
feature of mRNA-display, is necessary to completely cover all protein sequences with
desired characteristics. Additionally, numerous copies of each gene and its individual
domains can be found in an mRNA-displayed proteome library. Therefore, this added
complexity increases the possibility of finding rare and diversity sequences in a given
selection.
In selection methods, the protein expression can be significantly influenced by the
environment where the library generated. Being a totally in vitro method, mRNA-display
permits the generation of fusion proteins from any candidate libraries, with the random
regions present in isolation or within the context of the fusion. In an mRNA-display-based
selection, the proteins are typically expressed in cell-free eukaryotic translation systems,
such as the rabbit reticulocyte lysate, allowing the synthesis of proteins with reasonable
post-translational modifications and correct folding [19]. In contrast, protein expression of
phage display relies on using the translational machinery in bacteria, whereas, yeast two-
hybrid is limited to yeast cells, thus, some sequences are poorly expressed [20,21]. In
ribosome display, the proteins are displayed on very large ribosomes; hence there would be
unpredictable interactions between the huge ribosome complexes with the target. The
mRNA-display cell-free expression system offers the generation of protein molecules with
presumably reduced bias with a large complexity.
One of the major challenges of most protein selection platforms is that some abundant
sequences, either specific or nonspecific binders, may dominate the pool as selection
proceeds from one round to the next. Experimentally, in selections using unnormalized
natural cDNA libraries, the most abundant mRNA species could be more than thousands of
times higher than the least abundant ones [22]. In mRNA-display-based selection, abundant
sequences that obscure the discovery of rare, potentially interesting sequences, can be
efficiently subtracted at the mRNA level because the genotype of each molecule in the
selected pool is covalently linked with its own protein or peptide sequence [8,9,23]. This
unique feature significantly increases the chance of discovering rare sequences.
Another advantage of mRNA-display over other methods is the use of long proteins for
selection. In an mRNA-displayed protein library, the protein length is typically between 50–
300 amino acids. It is possible to generate larger proteins by DNA fractionation and
purification of the cDNA library using agarose gels. Inarguably, peptides or proteins of this
size (5.5–33 kDa) are much more likely than short ones to adopt native conformations,
allowing the identification of residues or motifs that play a role in mediating protein–protein
interactions or enzyme-substrate recognitions [9,24].
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Random mutagenesis, by PCR-based methods such as error-prone PCR, DNA shuffling,
random insertion and deletion, and random insertional-deletional strand exchange, is widely
utilized to introduce mutations in directed evolution for the isolation of sequences with
desirable characteristics [25]. Due to the necessity to perform ligation and transformation of
PCR products into cells, the use of mutagenesis approaches is limited in in vivo screening
methods. mRNA-display uses PCR to amplify the cDNA following each round of selection
and as such is readily compatible with PCR-based mutagenesis techniques.
1.3. Limitations of mRNA-display selection
In the previous section mRNA-display’s powerful features were described. However, the
method has some limitations. Even though large proteins may be displayed at lower
efficiency, mRNA-display works better when the displayed proteins size is less than 300
residues [26]. Moreover, protein interactions that depend on the formation of complexes
with their binding partners are difficult to address via mRNA-display. Due to the limited
expression of membrane-bound proteins by in vitro translation systems, mRNA-display
cannot be utilized to address membrane protein related questions [27]. mRNA-display–
based selection is relatively difficult to perform because of the manipulation of protein,
DNA and RNA in an RNAse-free environment and requires extensive expertise [26].
Another concern is whether the covalently attached mRNA portion interferes with the
function of the displayed protein or with the interaction between the target molecule and the
displayed protein. The interference of interaction is possible when the mRNA is present as
the flexible single-stranded form, particularly for proteins that nonspecifically bind to
nucleic acids. In addition, the mRNA portion of the fusion molecules is highly negatively
charged, which might interfere in a selection where the target is highly positively charged
[28]. Furthermore, some protein sequences may not be efficiently enriched because the
biases of mRNA-display depend on several factors, namely, the abundance in the initial
mRNA library, the overall efficiency of amplification, the efficiency of protein expression,
formation of mRNA-protein fusion and its interaction with the target.
To continually improve this technology several attempts have been made to address the
limitations of mRNA-display. To improve the stability of the fusion molecules, the single-
stranded mRNA of the fusion can be converted to an mRNA/DNA hybrid after the fusion
formation. A variant of mRNA-display, called cDNA-display, has been developed [29–31].
Selections using mRNA-display can also be performed by using microfluidic systems that
provide more efficient separation and purification [32]. However, the cost for higher
enrichment efficiency is the loss of the ability to obtain binding partners with low affinity,
which could be very useful for many applications.
1.4. Types of biological and biochemical questions that can be addressed by mRNA-
display
1.4.1. Applications using synthetic libraries—mRNA-display can be employed to
select peptides or protein sequences with desired features from synthetic combinatorial
libraries that contain varying length of totally or partially randomized amino acids, to
address a number of biological problems, including the discovery of binding partners for
both proteins and small molecules, and the discovery of novel enzymatic activities from the
peptide sequence space. Specifically, synthetic libraries have been used to identify peptides
that bind to streptavidin, the small molecule ATP, GPCR (G protein-coupled receptors)
Methuselah (Mth), calmodulin (CaM) and thrombin [33–37]. For example, in an effort to
search for ATP binding peptides, Keefe and coworkers showed that an in vitro selection of
an mRNA-displayed peptide library, composed of peptides containing 80 contiguous
random amino acids, yielded four new ATP binding proteins that appear to be unrelated to
each other or to anything found in the current databases of biological proteins [34]. Ja and
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coworkers demonstrated that mRNA-display can be used to identify peptides that bind to
Methuselah (Mth), a class B GPCR, with high affinity (Kd = 15–30 nM) from a 39-residue
synthetic library with 27 totally randomized amino acids. Significantly, the optimized
peptides could function as antagonists, and Drosophila melanogaster expressing these Mth
antagonistic peptides could extend their life span presumably by binding to the N-terminal
ectodomain of Mth and inhibiting the Mth signaling pathway [35]. mRNA-display has been
utilized to synthesize and select peptides with many unnatural amino acids [38]. In
particular, using a reconstituted Escherichia coli translation system, Szostak and coworkers
demonstrated that the reprogrammed genetic code could synthesize peptides with up to 13
different unnatural amino acids [39–41]. Unnatural peptide libraries of 1014 unique members
may be synthesized via mRNA-display using this translation system.
In addition to synthetic peptide libraries containing totally randomized cassettes, various
protein domain libraries with randomized binding loops have also been used for mRNA-
display-based selections in an effort to generate target-binding affinity molecules. These
protein domains include the 10th fibronectin type III domain (FN3), single chain antibody
fragment (scFv), and zinc finger-containing retinoid-X-receptor (RXR) scaffold. Xu and co-
workers created an FN3-based domain library by randomizing the three loops, including BC,
DE, and FG, that could be involved in target interaction and used it for the selection of TNF-
alpha-binding FN3 domains that bind TNF-alpha with low pM affinities [42]. By coupling
with error-prone DNA shuffling, Fukuda and co-workers demonstrated the selection and
affinity improvement of fluorescein-binding sequences from an mRNA-displayed single-
chain antibody fragment (scFv) library [11]. Similarly, Cho and Szostak identified protein
domains that specifically bound to ATP with moderate to high affinities, but not GTP, from
a protein domain library based on the DNA binding domain of human retinoid-X-receptor
(RXR) in which the two closely juxtaposed recognition loops were extensive randomized
[43]. To inquire the amino acid sequence space, Seelig and Szostak used an mRNA-
displayed RXR scaffold library with very high diversity to evolve synthetic proteins with
genuinely novel RNA ligase activities [44]. It was shown that new enzymatic activities can
be created de novo without the need for prior mechanistic information by selection from
such naive protein domain library. Potentially, novel enzymes that catalyze other
biochemical reactions may be discovered in this manner [44].
1.4.2. Applications using natural proteome libraries—In addition to synthetic
libraries generated from randomization of amino acids, natural libraries derived from the
mRNAs of tissues have also been used for mRNA- display-based selection to understand
biological problems such as drug-protein, protein-protein and nucleic acid-protein
interactions. The large library size achievable through mRNA-display allows for a
comprehensive coverage of potential targets in a proteome of interest and therefore creation
of network maps important for understanding the relevant signaling pathways. In the
application of drug-protein interactions, McPherson and coworkers demonstrated that
FKBP12 (FK506 binding protein 12 kDa), the physiological binding partner of
immunosuppressive drug FK506, could be readily identified using FK506-biotin as the bait,
from an mRNA-displayed human proteome library constructed from human liver, kidney,
and bone marrow transcripts [6]. Hammond and coworkers used mRNA-display to isolate
the binding partners of the anti-apoptotic protein Bcl-XL from a mixture of four libraries
derived from human kidney, liver, bone marrow, and brain tissue, each barcoded with an 8-
nucleotide tag within the 5’-UTR that can be deconvoluted with library-specific primers [4].
The selection resulted in the identification of three members of the Bcl-2 family known to
bind to Bcl-XL and several novel Bcl-XL binding partners. Using mRNA-display-based
selections, the binding partners of the basic leucine zipper domain (amino acids 167–319) of
the transcription factor Jun have been described [7]. Sixteen novel Jun-associated protein
candidates, in addition to four known interactors, were identified. Shen and coworkers
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scanned the human and C. elegans proteomes for Ca2+/CaM-binding proteins using an
mRNA-display proteome library constructed from mRNAs of the brain, heart, spleen,
thymus, and muscle tissues of human and of the adult worm, respectively [9,24]. A large
number of both known and previously uncharacterized proteins that interact with CaM in a
Ca2+-dependent manner were identified. From an mRNA-displayed mouse brain proteome
library, Tateyama and co-workers demonstrated the binding partners of the TPA-responsive
element (TRE) can be efficiently identified [10]. These studies demonstrate that mRNA-
display is a robust approach for the comprehensive mapping of the protein-protein and
nucleic acid-protein interaction networks at a proteome-wide scale.
mRNA-display has also been used to study the challenging enzyme-substrate interactions.
Cujec and coworkers investigated the substrate specificity of the kinase v-ABL using
mRNA-displayed random peptide and human bone marrow libraries [5]. Ju and coworkers
developed a high-throughput screen platform based on mRNA-display for the identification
of caspase family member specific substrates on a proteome-wide scale [8]. The method can
be widely applied for efficient and systematic identification of the family member specific
natural substrate repertoire of any caspase in an organism of interest, in addition to that of
numerous other proteases with high specificity.
2. Reagent and equipment list
Oligo name Sequence (5′ to 3′) Purpose
Random primer TTNNNNNN First-strand cDNA library
synthesis












Forward library primer TTCTTATACGACTCACTATAGGGACAATTACT
ATTTACAATTACAATG
Library amplification
Reverse library primer ATAGCCGGTGCCAGATCCAGACATTCCCATAT
G
Library amplification
Reverse transcription primer TTTTTTTTTTNNCCAGATCCAGACATTCCCAT Reverse transcription
Tris-HCl (VWR, cat. no. EM-9210)
HEPES (Gibco, cat. no. 15630-106)
Glycine (VWR, cat. no. EM-4810)
First-strand buffer (5×). First-strand buffer is prepared with 250 mM Tris-HCl, pH
8.3, 15 mM MgCl2 and 375 mM KCl. The buffer is stable at − 20°C for at least 3
months.
Second-strand buffer (5×). Second-strand buffer is prepared with 200 mM Tris-HCl,
pH 7.5, 22 mM MgCl2 and 425 mM KCl. The buffer is stable at − 20°C for at least 3
months.
T4 DNA polymerase buffer (10×). To prepare T4 DNA polymerase buffer, mix 100
mM Tris-HCl, pH 7.9, 500 mM NaCl, 100 mM MgCl2 and 10 mM DTT. The buffer is
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stable at − 20°C for at least 1 month. Avoid excessive freeze-thaw cycles to prevent
oxidation of DTT.
T4 DNA ligation buffer (10×). To prepare T4 DNA ligation buffer, mix 500 mM Tris-
HCl, pH 7.6, 100 mM MgCl2 and 100 mM DTT. The buffer is stable at −20°C for at
least 1 month. Avoid excessive freeze-thaw cycles to prevent oxidation of DTT.
RNA polymerase buffer (10×). RNA polymerase buffer consists of 400 mM Tris-HCl,
pH 7.9, 60 mM MgCl2 and 20 mM spermidine. DTT is freshly added prior to the
reaction to a final concentration of 10 mM. The buffer is stable at − 20 °C for at least 1
month.
Oligo(dT) binding buffer (1×). Oligo(dT) binding buffer consists of 100 mM Tris-
HCl, pH 8.0, 1 M NaCl, 10 mM EDTA and 0.2% (vol/vol) Triton X-100. The buffer is
stable at room temperature (∼25°C) for at least 3 months.
Oligo(dT) wash buffer. Oligo(dT) wash buffer consists of 20 mM Tris-HCl, pH 8.0,
300 mM KCl and 0.1% (vol/vol) Tween-20 (may be omitted if desired). The buffer is
stable at room temperature for at least 3 months.
TBST buffer (1×). To prepare TBST buffer, mix 20 mM Tris-HCl, pH 8.0, 150 mM
NaCl and 0.2% (vol/vol) Tween-20. The buffer is stable at room temperature for at least
3 months.
TE buffer (1×). To prepare TE buffer, mix 10 mM Tris-HCl, pH 8.0, and 1 mM EDTA.
The buffer is stable at room temperature for at least 3 months.
DNase buffer (10×). DNase buffer is prepared by combining 400 mM Tris-HCl, pH
8.0, 100 mM MgSO4 and 10 mM CaCl2. The buffer is stable at − 20°C for a least 1
month.
Glycine buffer, pH 3.5 (100 mM). After autoclaving, the buffer is stable at room
temperature for at least 1 month.
Preparation of left and right cassettes for ligation. The left and right cassettes are
prepared by PCR amplification, digested with either EcoRI or HindIII before use, and
then purified by agarose gel electrophoresis. The digested DNA fragments should be
prepared no more than a few days in advance and stored at 4 °C until use.
Acidic phenol/chloroform/isoamyl alcohol (Ambion, cat. no. AM9730)
LiCl RNA precipitation solution (7.5 M; Ambion, cat. no. AM9480)
Chroma Spin-1000 column (Clontech, cat. no. 636093)
QIAquick PCR purification kit (Qiagen, cat. no. 28104)
QIAquick gel extraction kit (Qiagen, cat. no. 28704)
Ethanol (EMD Chemicals, cat. no. EX0278-1)
Glycogen (Ambion, cat. no. AM9510)
Chloroform (EMD Millipore, cat. no. CX1054-1)
T4 DNA polymerase (NEB, cat. no. M0203)
NEB No. 2 buffer (NEB, cat. no. B7002S)
T4 DNA ligase (NEB, cat. no. M0202)
Synthetic deoxyoligonucleotides (Integrated DNA Technologies)
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5-Me dCTP (Fermentas, cat. no. R0431)
Methylation dNTP mix (10×; 10 mM of dATP, dTTP, dGTP, 5-Me dCTP;
ZymoResearch, cat. no. D1030)
RNase H (NEB, cat. no. M0297)
DNA polymerase I (NEB, cat. no. M0209)
T7 RNA polymerase (NEB, cat. no. M0251)
T7 RNA polymerase buffer, 10X
MgCl2 (VWR, cat. no. EM-5980)
rNTPs mix (25 mM) (Promega, cat. no. E6000)
Puromycin oligo linker:
5′-Psoralen-(TAGCCGGTG)m-(AAAAAAAAAAAAAAA)dC9C9(ACC)d-
Puromycin-3′ where, ( )m = 2’-O methyl RNA, ( )d = standard DNA, C9 = triethylene
glycol phosphoramidite (Spacer 9) (custom-synthesized at the W.M. Keck Oligo
Facility at Yale University)
Retic lysate IVT kit (Ambion, cat. no. AM1200)
[35S]-L-Met (PerkinElmer, cat. no. NEG009A05MC)
BirA enzyme (Biotin Ligase; Avidity, cat no. BirA500)
Biotin (Sigma, cat. no. B4639)
HABA (4′-hydroxyazobenzene-2-carboxylic acid) dye (Pierce, cat. no. 28010)
Nuclease-free water (Ambion, cat. no. AM9922)
NaCl (VWR, cat. no. EM-7710)
MgCl2 (VWR, cat. no. EM-5980)
KCl (VWR, cat. no. BDH4532-500GP)
CaCl2 (VWR, cat. no. EM-3000)
DTT (VWR, cat. no. EM-3860)
Spermidine (Sigma, cat. no. S0266)
Polyoxyethylene (20) sorbitan monooleate (VWR, cat. no. EM-9490)
EDTA disodium salt hydrate (VWR, cat. no. BDH4528-500GP)
Oligo(dT) cellulose (Ambion, cat. no. AM10020)
RNase-free 10-ml poly-prep chromatography column (Bio-Rad, cat. no. 731–1550)
Anti-FLAG M2 affinity gel (Sigma, cat. no. A2220)
FLAG peptide (Sigma, cat. no. F3290)
NAP-5 column (GE Healthcare, cat. no. 17–0853-01)
NAP-10 column (GE Healthcare, cat. no. 17–0854-01)
Streptavidin plus ultralink agarose resin (Pierce, cat. no. 53117)
BSA (Ambion, cat. no. AM2616)
RNase-free DNase (Promega, cat. no. M6101)
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SuperScript II RNase H − reverse transcriptase (Invitrogen, cat. no. 18064)
Diethylpyrocarbonate (DEPC) (Sigma, cat. no. D5758-100ML)
Sodium acetate (Ambion, cat. no. AM9740)
tRNA (Ambion, cat. no. AM7119)
dNTPs (Fermentas, cat. no. R0182)
dATP (Fermentas, cat. no. R0141)
Expand long template PCR system (Roche, cat. no. 11681842001)
Synthetic deoxyoligonucleotides (Integrated DNA Technologies)
Thermal cycler
NanoDrop spectrophotometer (Thermo Fisher Scientific)
UV lamp (Black Ray Lamp 365 nm, 0.16 Amps)
Labquake shaker/rotator (Barnstead)
Scintillation counter
Agarose and PAGE gel electrophoresis equipment
Gel documentation system
Microcentrifuge
Microcentrifuge tubes, nuclease- and RNase-free (e.g., Eppendorf tubes)
RNase-free PCR strip tubes
Vacuum concentrator (e.g., Speedvac)
Equipment for cloning and sequencing
Aluminum foil
3. Detailed Description of Methods
3.1. Overview of the procedure
One round of mRNA-display-based selection typically requires the following steps: in vitro
transcription, DNase digestion, conjugation with the puromycin oligo linker, in vitro
translation/fusion formation, oligo(dT) mRNA purification, reverse transcription, protein
affinity purification, pre-selection or functional selection, and regeneration of the selected
sequences. In more detail, the newly constructed library serves as template for in vitro
transcription to synthesize mRNAs that will be conjugated with the puromycin-containing
linker. Conjugation is achieved by hybridization of the purified mRNA with the psoralen-
and puromycin-containing linker, followed by UV cross-linking to form a stable 3’ terminal
hairpin. Other methods have been used to introduce the puromycin moiety needed for fusion
formation including enzymatic splint- and Y-ligations [3,45–47]. In vitro translation, using
puromycin-containing mRNAs as templates, is performed using rabbit reticulocyte lysate to
express the proteins. Fusion formation is initiated, after translation, by the addition of high
concentrations of Mg2+ and K+ to favor the reaction between puromycin at the 3’ end of the
mRNA strand with the C-terminus of the nascent proteins. The poly(dA) tract on the
oligonucleotide linker is used to purify the fusion molecules from the rabbit reticulocyte
lysate via oligo(dT) resin. A second fusion purification is accomplished by using protein
affinity tags on the N or C termini. Prior to the start of the selection, one round of pre-
selection is typically performed to remove out-of-frame sequences and those with stop
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codons following the cDNA library construction. The sequences included in the pre-selected
library can be characterized by deep sequencing or by using cDNA microarrays, when
available, for the organism or tissue of interest [48].
3.2. Generation of the random library
The random cassette can be synthesized on a DNA synthesizer using standard
phosphoramidite chemistry [49]. For the combinatorial peptide library, we used a pre-
selected, high-quality DNA library that codes for peptides with 20 consecutive random
amino acids as templates for in vitro transcription and translation [49]. Each sequence in the
DNA library contains a T7 RNA polymerase promoter, a TMV translation enhancer
sequence, an N terminal FLAG tag coding sequence, a random cassette encoding 20
consecutive random codons, and a C terminal His×6 tag coding sequence. Any cDNA
libraries that encode short peptides with either balanced or appropriately biased amino acid
compositions can be readily generated. This can be realized by using three phosphoramidite
mixtures with appropriate proportions of each of the four phosphoramidites during DNA
synthesis, corresponding to each of the three positions in the random codons.
3.3. Generation of the natural library
Useful natural libraries for mRNA-display can be created from any organisms, including
Caenorhabditis elegans, Drosophila melanogaster, mouse and human, at different
developmental stages, ages, tissues and treatments [8,9,24]. In general terms, the generation
of an mRNA-displayed proteome library starts by making a cDNA library that contains all
possible open reading frames. The cDNA library is made from high-quality poly (A+)
mRNA by stringent oligo (dT) purification to remove genomic DNA, rRNA and tRNA. To
permit nonbiased coverage of all genes, first-strand cDNA synthesis is performed through
reverse transcription by using a degenerate primer TTNNNNNN. Second-strand synthesis is
performed by DNA polymerase I in the presence of RNase H. 5-Me dCTP is used during the
synthesis of both cDNA strands as a way to make the ORF regions resistant to restriction
digestion when the linker and cassette are ligated. T4 DNA polymerase mediated blunt end
formation is followed by the ligation of a directional linker (EcoRI/HindIII linker) to permit
the ligation of the left cassette (containing a T7 promoter and a deletion mutant of the
tobacco virus 5’ untranslated region for efficient in vitro transcription and translation) and
right cassette (contains a short sequence for hybridizing with the puromycin-containing
oligo linker) with different consensus sequences. Affinity tags such as FLAG epitope, E
epitope, CaM-binding, AviTag, Myc, or His×6, may be incorporated at both ends for
purification or immobilization of mRNA-displayed proteome library during selection.
Amplification of the library is accomplished by using two common primers complementary
to the consensus T7 promoter and 3’ linker-hybridization region at the 5’ and 3’ end,
respectively. The cDNA library with desired length is then purified and recovered.
3.3.1. Step by step procedure for the generation of a natural library
1. First-strand synthesis. Prepare premix A in a nuclease-free microcentrifuge tube
on ice, as described in the table below:
Component Amount per reaction (µg) Final concentration
mRNA from species/tissue of choice 0.5–5 0.01–0.1 µg/µl
Random primer 0.125–1.0 —
Nuclease-free water To a final volume of 30 µl —
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2. Heat the mixture to 70 °C for 10 min and quickly cool on ice.
3. Centrifuge briefly to collect the contents.
4. Prepare premix B in a nuclease-free microcentrifuge tube on ice, as described in the
table below:
Component Volume per reaction (µl) Final concentration
First-strand buffer, 5× 10 1×
DTT, 100 mM 5 10 mM
Methylation dNTP mix, 10× 2.5 0.5 mM each
Superscript II (200 U/µl) 2.5 10 U/µl
5. Combine premix A and B with gentle pipetting (final volume 50 µl).
6. Incubate the mixture at 25 °C for 2 min and then at 37 °C for 1 h.
7. Inactivate the enzyme by heating at 70 °C for 15 min and cool on ice.
8. Second-strand synthesis. Assemble the following in a nuclease-free
microcentrifuge tube on ice:
Component Volume per reaction (µl) Final concentration
First-strand product from Step 7 50 —
Second-strand buffer, 5× 30 1×
DTT, 100 mM 3.6 2.4 mM
Methylation dNTP mix, 10× 1.25 0.25 mM
DNA polymerase I (10 U/µl) 3 0.2 U/µl
RNase H (5 U/µl) 0.2 1 U per 150 µl
Nuclease-free water To a final volume of 150 µl —
9. Mix contents gently and incubate at 15 °C for 90 min.
10. Purify double-stranded cDNAs with the QIAquick PCR purification kit, according
to the manufacturer’s instructions. Dissolve the resulting cDNAs in 30 µl of TE
buffer and proceed immediately with blunt ending (Step 11).
11. Blunt ending the cDNA. Assemble the following in a nuclease-free
microcentrifuge tube on ice:
Component Volume per reaction (µl) Final concentration
Double-stranded cDNAs in TE 30 —
buffer from Step 10
T4 DNA polymerase buffer, 10× 5 1×
DTT, 100 mM 2.5 5 mM
dNTP mix (2.5 mM each) 2.0 0.1 mM each
T4 DNA polymerase (3 U/µl) 0.83 0.05 U/µl
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Component Volume per reaction (µl) Final concentration
Nuclease-free water To a final volume of 50 µl —
12. Mix gently and incubate at 11 °C for 20 min.
13. Purify the product with QIAquick PCR purification kit according to the
manufacturer’s instructions, and then dissolve the resulting blunt-ended cDNAs in
25 µl of TE buffer. Proceed immediately to Step 14.
14. Ligation with directional linker. Assemble the following 50 µl reaction in a
nuclease-free microcentrifuge tube on ice:
Component Volume per reaction (µl) Final concentration
Blunt-ended cDNA from Step 13 25 —
T4 DNA ligase buffer, 10× 5 1×
DTT, 100 mM 5 10 mM
ATP, 2.5 mM 2 0.1 mM
PEG4000, 50% 8 8%
Phosphorylated EcoRI/Hind III linker 3 3 µM
T4 DNA ligase (6 Weiss Units) 8 0.12 U/µl
Nuclease-free water To a final volume of 50 µl
15. Mix gently and incubate the mixture at 16 °C for 20 h.
16. Add 150 µl nuclease-free DEPC-water to the ligation product and extract with 200
µl phenol:chloroform:isoamyl alcohol (PCI = 25:24:1 vol/vol/vol).
17. Add 1 µl glycogen (10 mg/ml), 200 µl of 4 M ammonium acetate and 1 ml of 100%
ethanol; maintain at − 80 °C for 2 h to precipitate the ligated cDNAs.
18. Remove the supernatant after centrifugation at 12,000g for 10 min at 4 °C, and
rinse the pellet with 300 µl of 70% (vol/vol) ethanol twice.
19. Allow the pellet to dry and resuspend the product in 20 µl nuclease-free DEPC-
water.
20. Generation of sticky ends for ligation with cassettes. Assemble the following 50
µl reaction mixture:
Component Volume per reaction (µl) Final concentration
dsDNA from Step 19 20 —
NEB no. 2 buffer, 10× 5 1×
HindIII (100 U/µl) 1 2 U/µl
Nuclease-free water To a final volume of 49 µl
21. Mix gently and incubate the mixture at 37 °C for 2 h.
22. Add 1 µl of EcoRI-HF (100 U/µl).
23. Mix well and incubate at 37 °C for 4 h.
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24. Purify the digested dsDNA with the QIAquick PCR purification kit, according to
the manufacturer’s instructions, and elute the product in 50 µl of 10 mM Tris-HCl,
pH 8.0.
25. Pass the sample through a Chroma Spin-1000 column according to the
manufacturer’s instructions, and proceed immediately to ligation with left and right
cassettes (Step 26).
26. Ligation with left and right cassettes. Assemble the following 80 µl reaction
mixture:
Component Volume per reaction (µl) Final concentration
Digested cDNA from Step 25 50 —
T4 ligation buffer, 10× (NEB) 8 1×
Digested/purified EcoRI-HF left cassette (see Oligos
Table)
X —
Digested/purified HindIII right cassette (see Oligos
Table)
X —
T4 DNA ligase (6 Weiss U/µl) 8 0.6 U/µl
Nuclease-free water To a final concentration of
80 µl
27. Mix gently and incubate the ligation mixture at 16 °C for 20 h.
28. Size separation and PCR amplification of the cDNA library. Purify and
fractionate the ligation products with desired length distribution (i.e., 500 bp to 3
kb) using 1% (wt/vol) agarose gel electrophoresis.
29. Cut the gel containing PCR products greater than 500 bp and recover the cDNA
library with QIAquick gel extraction kit and dissolve the product in 100 µl TE
buffer.
30. Proceed to selection section 4.1.
3.4. Preparation of RNA and conjugation
mRNA is generated by in vitro transcription using the newly constructed cDNA library and
subsequently conjugated with the puromycin/psoralen-containing oligo linker that will be
used to covalently attach the protein portion in the next subsequent step. Conjugation is
achieved by hybridization of purified mRNA with psoralen/puromycin-containing oligo
linker followed by UV cross-linking, to form a stable 3’ terminal hairpin structure
[45,46,50].
3.5. Generation and purification of mRNA-protein fusion
Creation of the mRNA-protein fusion is performed by using puromycin-containing mRNA
as templates for protein synthesis. Specifically, in vitro translation is performed using a cell-
free system (i.e., rabbit reticulocyte lysate). Moreover, following translation a high
concentration of Mg2+ and K+ is added to promote efficient mRNA-protein fusion formation
[3,45]. To recover mRNA-containing molecules from the lysate, an oligo(dT) purification
step is performed by taking advantage of oligo (dA) residues in the puromycin-containing
DNA linker. To remove the secondary structures of mRNA that may interfere with the
selection step, the fusion molecules are often converted to DNA/RNA hybrids by reverse
transcription. The resulting mRNA-displayed proteome library is then purified on the basis
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of each of the affinity tags at the N and C termini and used for subsequent selection. The
genes included in the mRNA-displayed protein library can be characterized by using gene
chips, if such microarrays are available for the organism of interest or by conventional
Sanger sequencing a desired numbers of clones from transformed E. coli colonies.
3.6. Characterization of the selected library
The selected sequences displayed on mRNAs are characterized after several rounds of
selection to check whether these selected proteins possess the desired properties. There are
two factors that determine which round of selection is to be characterized or when the
selection needs to be stopped, namely, moderately high sequence diversity and percentage of
proteins in the pool with desired properties. For example, an important question in the field
of apoptosis or programmed cell death, carried out by a family of proteases known as
caspases, is what protein targets are specifically cleaved by a caspase of interest. To address
this question, we performed an mRNA-display selection to determine the substrates of one
of the caspase family members, caspase-3 (Fig. 1). In this example, sequences from rounds
3, 4 and 5 of the caspase-3 selection were PCR-amplified and cloned into a TOPO vector,
sequenced and analyzed by a high-throughput digestion assay [8]. At this time, it is
important to see how diverse each selected pool is. Higher diversity increases the probability
of finding novel target binding proteins or protease substrates. In the case of the caspase
selection, it was important to determine the number of unique genes from clones that were
sequenced. Alternatively, genes were identified by hybridizing labeled, transcribed RNA
from the selected pool to an expression microarray. By analyzing the intensity of each
sequence, it was readily distinguishable whether a sequence was present or absent. The
second step in determining whether to continue the selection or characterize a particular
round is to evaluate the percentage of the selected sequences that possess the desired
properties. In our case, we must determined what percent of proteins can be cleaved by a
protease of interest or what percent of selected sequences bind to a target of interest. For the
proteolytic selection, the cleavage of each selected protein sequence by a protease of interest
may be tested by an in vitro proteolytic assay, using 35S-radiolabeled protein generated by
coupled in vitro transcription and translation (TNT), in the presence or absence of a protease
inhibitor. mRNA display can also be performed without using radio-labeling [7], but the
interpretation of the enrichment signal should be cautious. Each reaction mixture is loaded
to a high resolution Tricine-SDS/PAGE for analysis. Numerous positive and negative
controls are tested to confirm that this in vitro proteolytic assay is robust, provided that the
protein of interest is translated well in rabbit reticulocyte lysate. In our caspase-3 selection,
we decided to characterize round 3 pool because among unique proteins from a total of 580
clones we picked up for analysis, 173 were translated well by the high-throughput in vitro
transcription and translation (TNT), among which 115 proteins (66%) were found to be
specifically cleaved by caspase-3 [8]. In this case, the diversity of round 3 was high,
meaning, there were many novel substrates that were likely to be found as well as a high
percent of all of substrates that were specifically cleaved by the caspase of interest.
3.7. Different selection scheme design
3.7.1. Salt, buffer, and pH—Successful selections that investigate protein-protein,
protein-drug and protein-enzyme interactions depend on the selection design that optimally
allows for specific enrichment of sequences with desired characteristics, while minimizing
nonspecific sequences that might be co-selected due to various biases [51]. To this end, the
highly stable covalent linkage between mRNA and protein permits the employment of many
types of selection with diverse and stringent conditions. The flexibility of being able to use
various selection conditions is important to distinguish proteins with desired characteristics
from nonspecific ones. The selection stringency can be carefully controlled and tuned by
using detergents, chelating agents, unusual pH, temperature and ionic strength, in addition to
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nonspecific or specific competitors, cofactors and metal ions, as long as they do not interfere
with the functions of the peptides or proteins [51]. In addition, the expression of the
displayed proteins in rabbit reticulocyte lysate allows for some post-translational
modifications, thereby enhancing their functionality during the selection. Furthermore, in
vitro protein expression in mammalian cell lysate also minimizes biases from misfolding or
subcellular transport in vivo.
3.7.2. Length of library and folding of proteins—Another tunable feature of mRNA-
display is the ability of an investigator to manipulate the length of the cDNA and
consequently protein size. Typically, we have used an mRNA-displayed proteome library
whose length of peptides ranges from 50 to 300 amino acids. The protein size distribution
can be changed as desired by fractionation of the initial cDNA library. Functionally, longer
proteins are much more likely than short synthetic peptides to adopt native conformations
involved in mediating protein–protein, protein-drug and enzyme-substrate interactions. Also,
the use of longer proteins during selection allows for the identification of motifs that play a
range of major or minor roles in these interactions.
4. Selection Results and Discussion
Successful mRNA-display based selections are highly dependent on a robust and effective
selection scheme [26]. In one hand, an appropriate selection scheme will result in the
isolation of proteins with desired characteristics after a few rounds. In contrast, poorly
designed selections will enrich irrelevant sequences that quickly overwhelm the regenerated
library pool. To aid in the selection of specific sequences, competitive elution, using the free
target following target immobilization, is an effective strategy that should be employed.
Furthermore, selection approaches based on ‘binary’ events, such as protease cleavage or
conditional binding in the presence or absence of a third partner or cofactor, can also be
effective in identifying proteins with desired characteristics after several rounds [8,9].
Key points on how to perform successful selections and procedures of two selection
examples, protein-protein and enzyme-substrate interactions, respectively, are described in
the following sections. The aim of the first selection was to identify Ca2+-dependent CaM
binding proteins and of the second selection was to identify the downstream substrates of a
protease of interest. In the design of the Ca2+-dependent CaM-binding protein selection,
gentle and competitive elution was applied by specifically eluting with EGTA to release the
bound mRNA-protein fusion molecules (Fig. 1). For the selection of the downstream
substrates of a protease, the proteome library was immobilized on streptavidin-agarose
beads through a single biotin residue introduced during in vitro translation. The addition of a
protease of interest results in cleavage of endogenous substrates present in the library and
release of mRNA-protein fusions from the agarose beads (Fig. 1). One major challenge in
understanding caspase-mediated signaling pathways is the identification of the caspase
family member-specific substrates. In our substrate identification platform, selective
identification of member-specific substrates can be readily achieved by first treating the
immobilized library with related caspases prior to the selection using the caspase of interest.
To identify the family member-specific substrates of a caspase or caspase-like enzyme
(granzyme B), for example, the immobilized proteome library is first incubated with other
caspase members to remove the overlapping, redundant substrates. The pre-cleared library is
then used for selection to enrich the natural substrates that are only cleaved by the protease
of interest, such as granzyme B, but not by other caspase members. Using this method, we
successfully identified many family member-specific substrates for different human caspase
family members and granzyme B [8] (Fig. 2).
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To minimize nonspecific sequences, there are several steps that should be employed to all
selections. The binding buffer should have RNase-free tRNA and BSA to reduce nonspecific
binding of fusion molecules to solid surfaces or immobilized targets. Only RNase- and
DNase-free reagents should be utilized in the selections. The wash stringency should be
tested prior to elution of each cycle by using both positive and negative control sequences to
determine the optimal stringency. In a target-binding selection, a stringent wash may
effectively remove nonspecific sequences that bind to the target, but may also result in loss
of the desired sequences if their binding to target is weak.
Another important parameter in any given selection is the number of selection cycles. Often,
the enrichment efficiency during each selection cycle is unknown; therefore, one approach is
to perform 3 to 4 rounds of selection followed by sequencing one 96-well plate of constructs
from the eluted pools obtained after each round. Analysis of the frequency of unique genes
present in each pool provides insight into the diversity and enrichment of each cycle. Pools
that are dominated by only several sequences may be unsuitable for further characterization.
Conversely, pools that show moderate enrichment of several sequences (<20%) may provide
greater diversity for validation screening.
4.1. Binding-based selection
1. Following the library construction, a large-scale amplification is performed by
setting up 100 separate 50 µl PCR amplifications of the cDNA library. As opposed
to small PCR amplifications that are sequentially performed by using the previous
PCR product for the amplification each time, this large-scale amplification prevents
decreasing the library diversity. Most of the resulting amplified cDNA library
should be stored − 80 °C and should serve as the starting point of many selections.
2. To start the binding selection, usually 100 separate 50-µl PCR amplifications of the
stock library should be setup as follows:
Component Volume per reaction (µl) Final concentration
Gel-purified cDNA library 1 —
Expand long template buffer no. 1, 10 × 5 1×
dNTP mix (2 mM each) 8.75 0.35 mM
Forward library primer (10 µM) 2.5 0.5 µM
Reverse library primer (10 µM) 2.5 0.5 µM
Expand long template Taq (5 U/µl) 0.7 3.5 U per 50 µl
Nuclease-free water To a final volume of 50 µl
3. Run the following PCR program:
Cycle number Denature Anneal Extend
1 95 °C for 2 min
2–17 (or up to 27) 95 °C for 30 sec 65 °C for 30 sec 68 °C for 6 min
Final 68 °C for 7 min
4. Analyze the PCR products by agarose gel (1%, wt/vol) electrophoresis to check the
length distribution of the cDNA library.
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5. The number of PCR cycles needed to amplify the library should be titrated on a
small scale first to avoid overamplification of nonspecific products.
6. Purify the DNA following the detailed instructions below.
7. Pool 500 µl of amplified cDNA library into 1.5 ml microcentrifuge tube and add
3.2 µl of 0.5 M EDTA (pH, 8.0).
8. Mix and briefly centrifuge.
9. Add 0.5 ml of PCI.
10. Mix 10 times and hold at room temperature for 5 min.
11. Centrifuge at 14,000 rpm for 6 min.
12. Remove the supernatant and repeat the PCI purification.
13. Remove the supernatant and purify the DNA by performing a chloroform
extraction
14. Transfer the supernatant and precipitate by the addition of 0.1 volumes of 3 M
KOAc and 2.2 volumes of 100% ethanol and store at −20 °C overnight.
15. Centrifuge at 4 °C for 20 min at 13,400 rpm and wash the pellet with 500 µl of 70%
(vol/vol) ethanol.
16. Dry the pellet at room temperature until dry and resuspend the DNA in 30 µl of
DEPC-water and quantify the library using a nanodrop spectrophotometer.
17. Generation of mRNA by in vitro transcription. Assemble the following in a
nuclease-free microcentrifuge tube on ice:
Component Volume per reaction (µl) Final concentration
cDNA library X 200 nM
T7 RNA polymerase buffer, 10× 50 1×
rNTPs mix (25 mM each) 100 5 mM
MgCl2 (1.0 M) 9.5 19 mM (or 25 mM including 6 mM in 1×
T7 RNA polymerase buffer)
T7 RNA polymerase (50 U/µl) 30 3 U/µl
Nuclease-free water To a final volume of 500
µl
18. Incubate at 37 °C for 6–12 h.
19. Add 30 µl of 0.5 M EDTA (1.2 equivalent of [Mg2+]) and incubate at room
temperature for 5 min to dissolve the white precipitate (magnesium
pyrophosphate).
20. Extract the reaction mixture with 530 µl of acidic phenol chloroform, followed by
500 µl chloroform.
21. Desalt the product using NAP-5 column and collect the product in 1 ml of
nuclease-free DEPC-water.
22. Concentrate the sample to 400 µl in a vacuum concentrator.
23. Removal of cDNA from mRNA by DNase digestion. Assemble the following in a
nuclease-free microcentrifuge tube:
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Component Volume per reaction (µl) Final concentration
Desalted in vitro transcription product from Step 9 400 —
DNase buffer (10×) 50 1×
RNase-free DNase (1 U/µl) 25 0.05 U/µl
Nuclease-free water To a final volume of 500 µl
24. Incubate at 37 °C for 30 min.
25. Add 13.2 µl of 0.5 M EDTA to stop the reaction.
26. Extract the reaction mixture with 500 µl of acidic phenol chloroform, followed by
500 µl of chloroform.
27. Desalt using NAP-5 column and collect the product in 1 ml of nuclease-free DEPC-
water.
28. Add 500 µl (0.5 volumes) of 7.5 M LiCl RNA precipitate solution and incubate at −
80 °C for 2 h.
29. Spin at 13,200 g for 15 min at 4 °C and wash the pellet with 500 µl of 75% (vol/
vol) ethanol.
30. Allow the pellet to air-dry until no ethanol is detectable. Resuspend the purified
mRNA in 150 µl nuclease-free DEPC-water.
31. Measure optical density (OD) using the NanoDrop; calculate the molar
concentration of mRNA on the basis of the average length of the cDNA library.
32. Conjugation with puromycin-containing oligo linker. Assemble the following
reaction mixture:
Component Volume per reaction (µl) Final concentration
500 mM HEPES, pH 7.4 10 20 mM
KCl (500 mM) 50 100 mM
Purified mRNA from Step 17 (1.25 nmol) X 5 µM
Puromycin-containing oligo linker 3.125 nmol 12.5 µM
Nuclease-free water To a final volume of 250 µl
33. Mix well and aliquot 50 µl of the sample into an RNase-free eight-strip PCR tube.





1 85 °C for 8 min
2 80 °C for 60 sec
3 − 1 °C every 20 sec until 25 °C is reached
4 25 °C 25 min
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35. Transfer strip tubes to an ice bath and irradiate by using UV light at 365 nm for 20
min at 4 °C. Exposure to UV light results in cross-linking between the puromycin
linker and RNA through activation of the psoralen linker.
36. Pool the samples into an RNase-free 0.5-ml microcentrifuge tube.
37. Add 125 µl (0.5 volumes) of LiCl precipitate solution and incubate at − 20 °C for 4
h to precipitate RNA.
38. Wash the pellet with 250 µl of 75% (vol/vol) ethanol, air-dry the pellet and
resuspend the RNA product in 100 µl DEPC-water.
39. Measure OD using the NanoDrop and calculate the molar concentration of RNA.
40. In vitro translation and fusion formation. Assemble the following reaction
mixture as follows:
Component Volume per reaction (µl) Final concentration
Translation mix without Met, 12.5× 40 1×
KCl (2.0 M) 12.5–30 50–120 mM
Mg(OAc)2 (25 mM) 6–20 0.3–1.0 mM
Puromycin-linked mRNA templates (from
Step 25)
200 nM (assuming 40% cross-linking
efficiency at Step 22)
—
[35S]-L-Met (10 µCi/µl) 20 —
Retic lysate 200 40%
Nuclease-free water To a final volume of 500 µl
41. Incubate at 30 °C for 90 min. If the introduction of a biotin residue at the N
terminus of the protein moiety (with an AviTag engineered) is desired for
immobilization of the mRNA-displayed proteome library, add 10 µg of purified
BirA enzyme, 50 µM free d-biotin and 10 mM Mg2+/ATP to the translation
reaction mixture and incubate at 30 °C for another hour.
42. Add 38 µl of 1 M MgCl2 (final concentration 50 mM) and 220 µl of 2 M KCl (final
concentration 580 mM), mix gently (total volume 758 µl) and incubate at room
temperature for 30 min.
43. Incubate at − 20 °C overnight.
44. Oligo(dT) purification to remove free proteins. Weigh 60 mg of oligo(dT)
cellulose into a 1.5-ml nuclease-free microcentrifuge tube.
45. Wash cellulose beads three times with 1 ml of nuclease-free DEPC-water, and two
times with 1 ml of oligo(dT) binding buffer.
46. Resuspend oligo(dT) cellulose in 1 ml of binding buffer and transfer to a 15-ml
tube containing 9 ml of oligo(dT) binding buffer and 1 mM DTT.
47. Add the post-translation mix (758 µl from Step 30) to the slurry, wrap the tube in
aluminum foil and rotate for 2 h at 4 °C.
48. Load the slurry mixture into a 10 ml nuclease-free poly-prep chromatography
column.
49. Collect flow-through and reload to the resin bed; retain the final flow-through.
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50. Wash oligo(dT) cellulose on the column twice each with 1 ml of oligo(dT) binding
buffer, followed by three times each with 1 ml of oligo(dT) wash buffer; retain
each wash fraction.
51. Elute mRNA and mRNA-protein fusion molecules four times each with 600 µl of
DEPC-water plus 1 mM DTT.
52. Take 1/100 of each fraction and quantify the radioactivity using a liquid
scintillation counter. The quantity of radioactivity present in the final wash step
should be at baseline to ensure that unincorporated Met is fully removed. Elution
fractions typically show stepwise elevations in radioactivity with the highest counts
in the second or third elution fractions. Typically, the second elution fraction is
sufficient for subsequent steps if it shows the majority of the radioactivity.
53. Reverse transcription. Assemble the following reaction mixture and incubate at
room temperature for 15 min:
Component Volume per reaction (µl) Final concentration
Oligo(dT) elution fraction (from Step 38) 600
Reverse-transcription primer (50 µM) 50 2.5 µM
First-strand synthesis buffer, 10× 100 1×
dNTP mix (5 mM each) 100 0.5 mM each
DTT, 1M 9.4 10 mM
Nuclease-free water To give a final volume of 975 µl
54. Add 25 µl Superscript II (200 U/µl) to the mixture from Step 40 to yield a final
concentration of 5 U/µl. Incubate the reaction mixture at 42 °C for 50 min.
55. Add EDTA to 3.6 mM (1.2× [Mg2+]).
56. Exchange the buffer by applying to a NAP-10 column equilibrated with 1× TBST
buffer.
57. Collect the reverse-transcribed product in 1.35 ml of 1× TBST buffer.
58. Anti-FLAG purification to remove free mRNA. Quickly wash 600 µl of anti-
FLAG M2 affinity resin in a 10-ml poly-prep chromatography column five times,
each with 1 ml of 100 mM glycine buffer at pH 3.5.
59. Wash the resin three times, each with 5 ml of 1× TBST buffer.
60. Cap the bottom of the column and load the product (1.35 ml) from Step 43.
61. Cap the top of the column with a lid, and rotate at 4 °C for 2 h at a 45 °C angle
such that the resin is mixed well and stays at the bottom of the column. Prevent
mRNA-displayed protein loss during this purification step by minimizing the
attachment of solution beads to the top and sides of the chromatography column by
maintaining a proper rotation angle.
62. Place the column upright and allow the resin to settle for 2 min. Remove top and
bottom caps and collect the flow-through.
63. Wash the resin five times, each with 1 ml of 1× TBST, and collect each wash
fraction.
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64. Cap the bottom of the column and add 60 µl of 1× TBST plus 30 µl of 5 mg/ml
FLAG peptide to the slurry and rotate at 4 °C for 30 min to elute the captured
fusion molecules.
65. Collect the elution fraction and repeat Step 51 three times.
66. Take 1/100 of flow-through, wash and elution fractions and count the amount of
fusion molecules recovered with a liquid scintillation counter.
67. Functional selection using mRNA-protein fusion molecules. This step should be
designed and optimized for each different selection experiment. Here we provide
examples of two different selection schemes that could be modified as required.
Option A outlines a scheme for selecting protein-protein interactions. Option B
outlines a scheme for selecting substrates of a specific protease.
A) selection for conditional (Ca2+-dependent) protein-protein interactions
i. Dilute purified mRNA-displayed proteome library from
Step 53 in 0.5–2.0 ml of an appropriate binding buffer.
For selection of Ca2+-dependent calmodulin-binding
proteins, the binding buffer contains 50 mM Tris-HCl, pH
7.5, 150 mM NaCl, 0.05% Tween-20, 1 mg/ml BSA, 5
mM 2-mercaptoethanol and 0.5 mM CaCl2.
ii. Apply the mRNA-displayed proteome library to a
precolumn of 100–300 µl streptavidin plus ultralink
agarose beads. Collect the flow-through.
iii. Incubate flow-through with 5–25 µg of biotinylated target
protein (i.e., biotinylated calmodulin) for 30–90 min at 4
°C. Note: It is important to measure the average number
of biotin per target protein by using a colorimetric biotin
quantification assay based on the use of the HABA
reagent. Ideally, one biotin per target molecule is desired.
iv. Add the same amounts of prewashed streptavidin-agarose
beads as in Step 54A(ii) (100–300 µl) to the mixture and
incubate for 30 min at room temperature to capture the
biotinylated target protein complexed with its binding
partners.
v. Load the slurry mixture into an empty nuclease-free 10 ml
poly-prep chromatography column and wash unbound
molecules from the column with 9–24 column volumes (3
× 3–8 × 3 column volumes) of binding buffer.
vi. Elute the fusion molecules that bind to calmodulin in a
Ca2+-dependent manner using 1 column volume of
elution buffer containing chelating agent (binding buffer
minus CaCl2 plus 2 mM EGTA) four times.
vii. Collect each elution fraction, desalt with NAP-10 column
in DEPC-water and proceed with regeneration (Step 54).
4.2. Cleavage-based selection
B) Selection for the downstream substrates of a protease of interest
Valencia et al. Page 21













i. Dilute the purified mRNA-displayed proteome library from Step 53 in
0.5–2.0 ml of an appropriate reaction buffer for the protease of interest.
For selection of the downstream substrates of human caspases, for
example, the reaction buffer contains 50 mM HEPES, pH 7.4, 50 mM
NaCl, 0.1% (vol/vol) CHAPS, 5% (vol/vol) glycerol, 1 mg/ml BSA, 10
mM DTT and 10 mM EDTA.
ii. Apply the proteome library to a precolumn of 100 µl agarose beads.
iii. Collect the flow-through and apply to a new column of 100 µl
streptavidin plus ultralink agarose beads. Incubate for 1 h at room
temperature to immobilize the biotinylated mRNA-protein fusion
molecules on the resin.
iv. Wash unbound molecules with 250 column volumes of protease
reaction buffer. This helps to lower the number of false positive
molecules passing through the column before protease-mediated
digestion. Add an appropriate amount of a highly purified protease of
interest (free of nucleases and other proteases) in the reaction buffer
and incubate for 30–90 min at 37 °C with rotation.
v. Collect flow-through of the proteolytic reaction, desalt with NAP-10
column in DEPC-water and proceed with regeneration (Step 54).
54. Regeneration of the selected sequences. Assemble the following reaction
mixture:
Component Volume per reaction (µl) Final concentration
Eluted fusion molecules in nuclease-free water 70 70%
Forward library primer (15 µM) 2 300 nM
Reverse library primer (15 µM) 2 300 nM
dNTP mix (5 mM each) 7 0.35 mM
Expanded long template PCR buffer, 10× 10 1×
Long template Taq enzyme (5 U/µl) 1 5 U per 100 µl
Nuclease-free water To a final volume of 100 µl
55. Mix well and aliquot 15-µl samples into six different PCR tubes.
56. Run the following PCR program:
Cycle number Denature Anneal Extend
1 95 °C for 2 min
2–16 (or up to 31) 95 °C for 30 sec 65 °C for 30 sec 68 °C for 6 min
Final 68 °C for 7 min
57. Remove a PCR tube at cycles 15, 18, 21, 24, 27 and 30, respectively. Transfer
all tubes back to the thermocycler for the last extension step (68 °C for 6 min).
58. Run each sample on a 1% (wt/vol) agarose gel to determine how many cycles of
PCR are necessary to regenerate the library without overamplification.
Overamplification occurs when too many cycles of PCR are performed on a
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library resulting the upward skewing of the library length. To prevent
overamplification, a small volume of the library to be amplified is used as a
template and numerous amplification cycles are tested. The PCR products of
various cycles are separated and compared on an agarose gel and the lane with
the highest amount of DNA, based on intensity, having the expected average
size should be the library to be used for subsequent steps.
59. Repeat the PCR outlined in Steps 54–56 on a large scale using 30–80% of the
selected molecules. Clone, sequence and bioinformatically analyze the selected
molecules.
60. To begin the next round of selection, carry out in vitro transcription (Step 4) on
the regenerated cDNA library and repeat the entire selection cycle (Steps 4–59)
4.3. Selection results analysis
4.3.1. Bioinformatics—After appropriate rounds of selection, hundreds of clones are
typically sequenced and identified by BLASTing the selected sequences or by hybridizing
the selected sequences onto cDNA microarrays (Fig. 1). Once identified, the percent of
unique clones that bind to target or is cleaved by a protease of interest is determined. Once
the identity of the clones has been determined, the binding or cleavage sites can be easily
mapped (Fig. 3). Typically, the selected sequences are often isolated as multiple fragments
of different lengths derived from the same parental ORF, and the shortest overlapping region
can be readily mapped [8,9]. Based on the results from many known caspase substrates
isolated from the selection, the shortest overlapping region often contains the cleavage
site(s). Similarly, in the CaM binding protein selection, the shortest fragments indicated the
motifs involved in binding to CaM, thus, known and novel Ca2+/CaM-binding domains were
readily discovered.
Using this method, the cleavage sites of the selected caspase substrates were determined
following the caspase-substrate selection. Significantly, it was found that many of the
mapped cleavage sites are located within or close to a structural domain, suggesting that the
functions of these substrates could be altered or abolished by caspase-mediated proteolysis.
In general, the mapped cleavage sites are consistent with the assigned classes reported in the
literature [52]. In the case of caspase-3 substrates, P1 (amino acid that is C-terminally
cleaved, additional sites are N-terminal from P1 labeled as P2, P3, etc.) is completely
conserved with an aspartic acid, followed by P4, which is dominated by an aspartic residue.
P3 and P1 are not highly conserved, but glutamic acid and glycine occur at the highest
frequencies, respectively. At the P6, P5 and P2 positions, the variance is high, suggesting
these positions are not critical for enzyme specificity.
The CaM binding motifs are also easily mapped, specifically, by locating the shortest
overlapping region from different selected fragments of the parental protein. As an example,
among 499 clones analyzed from round 1 of the CaM binding protein selection, 14 were
from α-fodrin, a well characterized CaM-binding protein. These 14 protein fragments
ranged from 80 to 189 residues and overlapped from M1158-N1192
(MMPRDETDSKTASPWKSARLMVHTVATFNSIKELN)[9]. This 34 amino acid
fragment is just 14 amino acids longer than the previously mapped CaM-binding motif of α-
fodrin (A1169-I1188). Similar results were obtained from many other well characterized
CaM-binding proteins. The CaM-binding motifs in the previously uncharacterized CaM-
binding proteins were generally predicted to contain a positively charged amphiphilic α-
helix when the selected sequence fragments were analyzed by using a Web-based motif
analysis program called Calmodulin Target Database (http://calcium.uhnres.utoronto.ca/
ctdb/ctdb/sequence.html).
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A challenge in the proteome-wide selections is the interference of sequences that dominate a
selected pool. Fragments from several genes may be preferentially enriched, which could
interfere with the isolation of lower abundance substrates. However, mRNA-display offers a
solution by removing the abundant sequences from a given round of selection. Specifically,
after obtaining the identity of the abundant genes by sequencing a couple of hundred clones,
biotinylated antisense oligos are designed against the common region mapped by aligning
the abundant protein sequences derived from the parent proteins [23]. Following RNA
hydrolysis and neutralization, hybridization of the biotinylated oligos with the
complementary cDNA, and passage through a streptavidin column, it was found that these
abundant sequences were effectively removed. This unique feature significantly increases
the chance of discovering non-abundant protein binding partners or protease substrates [23].
4.3.2. Biochemical assays—Although after each round of selection there is a percentage
of proteins that have the desired characteristics, it is important to biochemically confirm the
enriched clones by a high-throughput assay to address cleavage or binding specificity,
inhibition, and kinetics. Several key features of mRNA-display are that the recovery of the
coding sequences from a selection allows for rapid identification, regeneration, and
functional characterization of the enriched proteins. Specifically, selected mRNA-display
molecules contain all the necessary sequences for efficient in vitro transcription and
translation, such as the T7 promoter, start codon, and Kozak sequences, and therefore can be
directly used as templates to regenerate the proteins. Since the proteins can be radiolabeled
with [35S]-methionine during coupled in vitro transcription and translation, highly sensitive
proteolytic or binding assays can be performed without using antibodies.
4.3.3. Protease-substrate orthologs in model organism—The identification of
novel human protease substrates, along with the readily mapped cleavage sites, will greatly
facilitate our understanding of such signaling pathways in other organisms. For example,
although caspase-3 in mouse and human (HCASP3) has been thoroughly investigated
enzymatically, its homolog in zebrafish has not yet been detailed. The amino acid sequence
identities of zebrafish caspase-3 (ZCASP3) with human, mouse, Drosophila, and C. elegans
caspase-3 are 62%, 61%, 42%, and 33%, respectively [53–55]. Functional analysis shows
that overexpressing ZCASP3 had caspase activity and induced apoptosis in fathead minnow
tailbud cells and zebrafish embryos [53]. Our knowledge about the signaling pathways
mediated by ZCASP3 is limited. To elucidate the potential ZCAP3 substrates, we examined
the conservation of the caspase-3 cleavage sites, found in the human caspase-3 selection, in
zebrafish orthologs (Fig. 4). These results prompted us to investigate whether the zebrafish
orthologs of these human caspase-3 substrates are indeed cleaved by ZCASP3. Among
approximately 60 novel human caspase-3 substrates we analyzed, 27 of them have the
putative DXXD cleavage sites conserved in their zebrafish orthologs. To examine whether
these zebrafish proteins were zebrafish ZCASP3 substrates, they were expressed and
subjected to a proteolytic assay (Fig. 4). Using this approach, we identified 14 natural
ZCASP3 substrates that have not yet been previously studied [56]. In general, the database
exploration approach can be used to define the function of homologous proteins in other
biological systems, including model organisms.
5. Conclusions
mRNA-display can be used to identify polypeptide sequences with desired functions from
both synthetic peptide and natural proteome libraries. mRNA-display has been used for
isolation of novel and improvement of existing affinity reagents, evolution of enzymes with
desired catalytic activities, identification of drug-binding targets, mapping and elucidation of
protein-protein, nucleic acid-protein, and enzyme-substrate interaction networks.
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Since we only rely on the presence of mRNA, mRNA-display can be widely used to address
various biological questions in any organism of interest. Its unique features, together with
the freedom of using arbitrary selection conditions, make mRNA-display-based selection an
ideal approach for the comprehensive cataloging of the proteins that participate in a specific
signaling pathway. In the biotechnology realm, mRNA-display selections have the great
potential to be applied for the development of novel affinity proteins against new biomarkers
for in vivo applications such as cancer drug delivery. Furthermore, mRNA-display may aid
in the discovery of next generation biopharmaceuticals that highly specifically block the
activation of signaling pathways.
mRNA-display is a totally in vitro peptide or protein selection method. Owing to its unique
features, we expect that this technique will be widely applied to investigate many different
types of biological questions that are difficult to address using other protein selection
techniques. In particular, it is ideal for the investigation of conditional protein–protein
interactions that rely on the present of a third partner. We expect that improvement will be
made to make mRNA-display suitable for selections using bioactive receptors on the surface
of living cells. We also expect that mRNA-displayed full-length proteins, such as all the
proteins involved in a particular signaling pathway, will be used to understand their
comprehensive protein–protein interaction networks and the regulatory mechanisms
governing them.
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Sample selection types. Schematic representation of the selection procedure for the natural
substrates of a protease of interest from an mRNA-displayed proteome library (Option A).
Schematic representation of the selection procedure for the binding partners of a target of
interest from an mRNA-displayed proteome library (Option B). mRNA, blue; DNA, black;
protein, orange; puromycin, pink circle labeled with a P; biotin, black circle labeled with a
B; streptavidin, black circle labeled with an S; agarose beads, yellow circle labeled as
agarose; protease, black scissors; target protein, red.
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Identification of two granzyme B substrates by using a selection procedure that allows the
identification of family member specific substrates. Prior to selection, the mRNA-displayed
proteome library is immobilized on a streptavidin-agarose matrix and cleaved with other
caspase members to remove the overlapping substrates. After stringent washing, the pre-
cleared proteome library was used to enrich for the family member-specific substrates that
are cleaved by the protease of interest, in this case, granzyme B (GB). The numbers 1 to 10
indicate the caspase used in the proteolytic assay. Caspase-10a and 10b refer the two
isoforms of caspase-10. The 35S-labeled full-length proteins are shown below (arrow).
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Cleavage site(s) or binding domain mapping diagram. After each round of selection, the
selected fragments are cloned into a plasmid and transformed bacteria are selected on an
antibiotic containing agar plate. Plasmid DNAs are extracted from the bacterial colonies and
sequenced. The sequence of each clone is bioinformatically translated to find the correct
reading frame. Often fragments of varying lengths from the same parental sequence appear
and the shortest sequence marks either the cleavage site(s), as in the diagram below, or
binding domain. Thus, the functional significance of the newly mapped cleavage site(s) can
be further tested by in vivo assays.
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In vitro proteolysis of full-length or fragment zebrafish proteins by ZCASP3, HCASP3, and
DCP1 identified by homology searches. Novel human caspase-3 substrates protein
sequences were BLASTed to check for mapped cleavage site homology with zebrafish
proteins. Below are four zebrafish proteins that contain conserved cleavage sites (red
letters).When digestion assays were performed on zebrafish proteins, the zebrafish caspase-3
(ZCASP3) efficiently digested zebrafish substrates. In contrast, when the zebrafish
substrates were cleaved by the ortholog human caspase-3 (HCASP3), inefficient cleavage of
all four substrates was observed, indicating a different enzyme specificity. The cleavage
pattern of the zebrafish substrates following zebrafish and human caspase-3 digestions was
not identical. Z in Z-stCAST is the zebrafish ortholog. FL indicates full-length protein and
FG means large fragment, when the full-length protein could not be expressed.
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